ATE376187T1 - Nachweis von erkrankungen der nieren und behandlung - Google Patents

Nachweis von erkrankungen der nieren und behandlung

Info

Publication number
ATE376187T1
ATE376187T1 AT99959616T AT99959616T ATE376187T1 AT E376187 T1 ATE376187 T1 AT E376187T1 AT 99959616 T AT99959616 T AT 99959616T AT 99959616 T AT99959616 T AT 99959616T AT E376187 T1 ATE376187 T1 AT E376187T1
Authority
AT
Austria
Prior art keywords
disease
kidneys
diseases
detection
treatment
Prior art date
Application number
AT99959616T
Other languages
English (en)
Inventor
Wayne Comper
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP7843A external-priority patent/AUPP784398A0/en
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of ATE376187T1 publication Critical patent/ATE376187T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
AT99959616T 1998-12-21 1999-12-20 Nachweis von erkrankungen der nieren und behandlung ATE376187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7843A AUPP784398A0 (en) 1998-12-21 1998-12-21 Kidney disease detection and treatment
US09/415,217 US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment

Publications (1)

Publication Number Publication Date
ATE376187T1 true ATE376187T1 (de) 2007-11-15

Family

ID=25645955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99959616T ATE376187T1 (de) 1998-12-21 1999-12-20 Nachweis von erkrankungen der nieren und behandlung

Country Status (13)

Country Link
US (3) US20020012906A1 (de)
EP (1) EP1141728B1 (de)
JP (2) JP4160263B2 (de)
CN (1) CN1331801A (de)
AT (1) ATE376187T1 (de)
AU (1) AU1674400A (de)
BR (1) BR9916407A (de)
CA (1) CA2356174A1 (de)
DE (1) DE69937368T2 (de)
DK (1) DK1141728T3 (de)
IL (1) IL143892A0 (de)
MX (1) MXPA01006404A (de)
WO (1) WO2000037944A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
IL143892A0 (en) 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US7172873B2 (en) 2001-03-28 2007-02-06 Heska Corporation Methods of detecting early renal disease in animals
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US7482128B2 (en) 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
ES2550952T3 (es) * 2004-11-24 2015-11-13 Hill's Pet Nutrition, Inc. Composición para su uso en la mejora del aclaramiento hepático de sustancias xenobióticas en un animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
US8647660B2 (en) * 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
AU2006236345B2 (en) 2005-04-19 2011-03-31 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
JP2008539274A (ja) * 2005-04-29 2008-11-13 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコの寿命を延長する方法
RU2372794C2 (ru) * 2005-05-20 2009-11-20 Хилл`С Пет Ньютришн, Инк. Способы укрепления здоровья или общего состояния взрослых животных
AU2006263651C1 (en) * 2005-06-29 2011-04-28 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
RU2377980C2 (ru) 2005-08-17 2010-01-10 Хилл`С Пет Ньютришн, Инк. Способы и композиции для профилактики и лечения заболеваний почек
CA2680198C (en) * 2007-03-07 2016-01-19 Mosaiques Diagnostics And Therapeutics Ag Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
CA2701571A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide markers for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
JP2011515672A (ja) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 腎尿細管の損傷および疾患の診断のための方法およびマーカー
ES2535640T3 (es) 2008-07-18 2015-05-13 Boston Medical Center Corporation Diagnósticos para nefropatía membranosa
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010031822A1 (de) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Nierenzellkarzinom
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (de) * 2008-10-21 2014-12-17 Astute Medical, Inc. Verfahren und Zusammensetzungen zur Diagnose und Prognose von Nierenläsion und Niereninsuffizienz
CN104330574B (zh) 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2364370B1 (de) * 2008-11-22 2014-09-03 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
WO2010064239A1 (en) 2008-12-04 2010-06-10 Technion Research And Development Foundation Ltd. Apparatus and methods for diagnosing renal disorders
DK2391653T3 (en) * 2009-01-28 2015-02-09 Ind Tech Res Inst Biomarkers associated nephropathy
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120061863A (ko) * 2009-08-07 2012-06-13 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
EA201290195A1 (ru) * 2009-11-07 2012-12-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
EP2539712A4 (de) 2010-02-26 2013-09-18 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
IN2012MN02812A (de) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8930222B2 (en) * 2010-08-05 2015-01-06 Abbott Laboratories Method and system for managing patient healthcare
DE102010038014B4 (de) * 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
KR101215759B1 (ko) 2010-11-01 2012-12-26 서울대학교산학협력단 오로소뮤코이드를 포함하는 조성물의 용도
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US20130115640A1 (en) * 2011-11-03 2013-05-09 James A. Tumlin ACTH for Treatment of Kidney Disease
EP3540440B1 (de) 2011-12-08 2022-09-28 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus
US9689826B2 (en) 2012-03-11 2017-06-27 Technion Research And Development Foundation Ltd. Detection of chronic kidney disease and disease progression
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016188761A (ja) * 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
WO2016012864A2 (en) * 2014-07-23 2016-01-28 University Of British Columbia Biomarkers for anderson-fabry disease
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107561175A (zh) * 2017-08-10 2018-01-09 武汉大学 一种肾小球硬化大鼠模型的评价方法
RU2697722C1 (ru) * 2018-12-06 2019-08-19 Ирина Сергеевна Шатохина Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
CN110632229A (zh) * 2019-09-24 2019-12-31 华兰生物工程重庆有限公司 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита
JP7854119B1 (ja) * 2024-12-25 2026-04-30 キリンホールディングス株式会社 免疫活性を判定する方法、及び免疫活性を判定するための装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry
EP0514928B1 (de) * 1991-05-24 1997-08-20 Wakamoto Pharmaceutical Co., Ltd. Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten
JPH0682446A (ja) * 1992-08-31 1994-03-22 Wakamoto Pharmaceut Co Ltd 腎疾患の診断法
DE4336498A1 (de) * 1993-10-26 1995-04-27 Bender & Co Gmbh Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen
US5534431A (en) * 1994-02-28 1996-07-09 The Board Of Regents Of The University Of Nebraska Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
IL143892A0 (en) 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment

Also Published As

Publication number Publication date
JP4388515B2 (ja) 2009-12-24
DE69937368D1 (de) 2007-11-29
US6589748B2 (en) 2003-07-08
CN1331801A (zh) 2002-01-16
EP1141728A4 (de) 2005-01-12
US20020012906A1 (en) 2002-01-31
WO2000037944A1 (en) 2000-06-29
US20020022236A1 (en) 2002-02-21
AU1674400A (en) 2000-07-12
DK1141728T3 (da) 2008-02-04
US20040106155A1 (en) 2004-06-03
JP4160263B2 (ja) 2008-10-01
IL143892A0 (en) 2002-04-21
JP2002533680A (ja) 2002-10-08
DE69937368T2 (de) 2008-07-17
MXPA01006404A (es) 2003-06-06
JP2006038877A (ja) 2006-02-09
EP1141728A1 (de) 2001-10-10
CA2356174A1 (en) 2000-06-29
EP1141728B1 (de) 2007-10-17
BR9916407A (pt) 2001-09-25

Similar Documents

Publication Publication Date Title
DE69937368D1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69530861D1 (de) Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays
DE69522831D1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
ATE361470T1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
ATE267399T1 (de) Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa)
ATE403745T1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
EP0165681A3 (de) Verfahren zum Nachweis von drogeninduzierter Thrombozytopenia und in diesem Verfahren zu verwendender Immunosatz
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
EA199800493A1 (ru) Анализ крови на соотношение активности фактора v для оценки вероятности заболевания тромбоэмболией
NO953770L (no) Analysemetode
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
EP1281083A4 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen
FI910324A7 (fi) Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
NO973823D0 (no) Påvisning av antistoffproduksjon
ES8707798A1 (es) Un procedimiento para analizar una muestra de tejido para determinar la presencia de antigeno de la hepatitis no a no b
ATE192236T1 (de) Menschliche phospholipase aktivierender proteinteil
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
DE60033190D1 (de) Verfahren zum nachweis von hepatitis c antigenen
ATE367582T1 (de) Verfahren zum nachweis von borna-disease-virus (bdv)- infektionen
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro
ATE232299T1 (de) Immunoassay zur bestimmung von psa-act
DE69809576D1 (de) Immuntest zum nachweis von menschlichen cytomegalovirus spezifischen igm
DE69533200D1 (de) Verfahren zur prüfung von immunokompetenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141728

Country of ref document: EP

REN Ceased due to non-payment of the annual fee